Table 3.
Univariate | Multivariable | |||
---|---|---|---|---|
3 Years Disease-free Survival Outcomes | ||||
HR (95%) | P | HR (95%) | P | |
Procedure (SILS + 1 vs. CLS) | 1.36(0.62–2.96) | 0.77 | 1.10 (0.49–2.41) | 0.82 |
Sex(Male vs. Female) | 1.25(0.57–2.76) | 0.58 | 0.96(0.43–2.12) | 0.91 |
Age(≤60 vs. >60) | 0.89(0.41–1.94) | 0.73 | 1.08(0.49–2.37) | 0.84 |
T stage(T1 + T2 vs. T3 + T4) | 4.32(1.02–18.28) | 0.047 | 2.51(0.58–10.89) | 0.22 |
N Stage (N0 vs. N+) | 8.22(3.10-21.83) | <0.001 | 7.10(2.61–19.29) | <0.001 |
5 Years Overall Survival Outcomes | ||||
HR (95%) | P | HR (95%) | P | |
Procedure (SILS + 1 vs. CLS) | 1.53(0.74–3.18) | 0.25 | 1.29(0.61–2.71) | 0.50 |
Sex(Male vs. Female) | 1.02(0.49–2.11) | 0.94 | 0.79(0.38–1.64) | 0.53 |
Age(≤60 vs. >60) | 0.95(0.46–1.95) | 0.88 | 1.11(0.54–2.31) | 0.77 |
T stage(T1 + T2 vs. T3 + T4) | 2.35(0.82–6.72) | 0.11 | 1.39(0.47–4.11) | 0.56 |
N Stage (N0 vs. N+) | 6.61(2.84–15.42) | <0.001 | 6.24(2.59–15.04) | <0.001 |
Abbreviation: HR, hazard ratio